Paper - WANFANG MED ONLINE

You Position: Home > Paper

Oral recombinant adeno-associated virus gene medicine

( views:10, downloads:0 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 7

DOI:: 10.3321/j.issn:0513-4870.2009.07.003

Key Word:: 口服给药;基因药物;腺相关病毒

Abstract：重组腺相关病毒(rAAV)载体介导的口服基冈药物引起业界广泛的重视.尽管经口服给药后转基因的有效表达面临许多障碍,但该技术的有效性已得到大量实验证实.本文总结了口服rAAV基冈药物的临床前研究结果,重点阐述了该类型药物的传递、吸收、分布和基冈转导等药动学特点.已证实rAAV基因药物对人体的安全性高,但口服rAAV基因药物的临床应用仍需对其作用机制和生物约剂学特征进行深入和广泛的研究.

Reference

[1]Jing Chen,Wu-Li Yang,GE Li,etc.Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles[J].2004,(1).
[2]李凤前,费轶博,苏华,等.疫苗口服接种及其微粒传输系统[J].2007,(3).
[3]Sferra TJ,Huang Q,Shao G,etc.Gene transfer to the gastrointestinal tract after peroral administration of recombinant adeno-associated virus type 2 vectors.[J].2006,43(2).
[4]Schultz BR,Chamberlain JS.Recombinant adeno-associated virus transduction and integration.[J].2008,16(7).
[5]许瑞安,马旭.载体经口服转导肝肠细胞[P].2003.
[6]刁勇,许瑞安,王广基,等.腺相关病毒介导的人红细胞生成素体外表达[J].2002,(1).
[7]Mueller C,Flotte TR.Clinical gene therapy using recombinant adeno-associated virus vectors.[J].2008,15(11).
[8]Rabkin SD,Varghese S.Oncolytic herpes simplex virus vectors for cancer virotherapy.[J].2002,9(12).
[9]Kleinschmidt JA,Bleker S,Leuchs B,etc.Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus[J].2006,80(22).
[10]Koseki H,Kato Y,Takano-Maruyama M,etc.Foxl1-deficient mice exhibit aberrant epithelial cell positioning resulting from dysregulated EphB/EphrinB expression in the small intestine.[J].2006,291(1).
[11]Nian M,Gu J,Irwin DM,etc.Human glucagon gene promoter sequences regulating tissue-specific versus nutrient-regulated gene expression.[J].2002,282(1).
[12]Osborne WR,Katen LJ,Lee SP,etc.Apical gene transfer into quiescent human and canine polarized intestinal epithelial cells by lentivirus vectors.[J].2000,74(16).
[13]M J, During,R, Xu,D, Young,etc.Peroral gene therapy of lactose intolerance using an adeno-associated virus vector.[J].1998,4(10).
[14]Laukoetter MG,Bruewer M,Nusrat A.Regulation of the intestinal epithelial barrier by the apical junctional complex.[J].2006,22(2).
[15]G. Gordon MacPherson,Neil A. Mabbott.Prions and their lethal journey to the brain[J].2006,4(3).
[16]Di Pasquale G,Chiorini JA.AAV transcytosis through barrier epithelia and endothelium.[J].2006,13(3).
[17]Takahashi K,Yuasa K,Monsonego A,etc.Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease.[J].2004,6(5).
[18]Sasakawa C,Jang MH,Yamamoto M,etc.Intestinal villous M cells: An antigen entry site in the mucosal epithelium[J].2004,101(16).
[19]S Wirtz,P R Galle,M F Neurath.Efficient gene delivery to the inflamed colon by local administration of recombinant adenoviruses with normal or modified fibre structure[J].1999,44(6).
[20]Wells JM,Mercenier A.Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria[J].2008,6(5).
[21]J W, Sandberg,C, Lau,M, Jacomino,etc.Improving access to intestinal stem cells as a step toward intestinal gene transfer.[J].1994,5.
[22]Ko SY,Cheng C,Kong WP,etc.Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors[J].2009,83(2).
[23]Bainbridge JW,Smith AJ,Barker SS,etc.Effect of gene therapy on visual function in Leber's congenital amaurosis.[J].2008,358(21).
[24]Kraehenbuhl J,Bogdanova A,Pringault E,etc.Molecular studies of the intestinal mucosal barrier physiopathology using cocultures of epithelial and immune cells: a technical update.[J].2000,2(9).
[25]Stachler MD,Bartlett JS,Ting AY,etc.Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase.[J].2008,16(8).
[26]Epperly MW,Wang H,Shen H,etc.Intraesophageal MnSOD-plasmid liposome enhances engraftment and self-renewal of bone marrow derived progenitors of esophageal squamous epithelium.[J].2008,15(5).
[27]Louise Y. Y. Fong,Kristoffel R. Dumon,Hideshi Ishii.FHIT gene therapy prevents tumor development in Fhit-deficient mice[J].2001,98(6).
[28]Bomsel M,Alfsen A.Entry of viruses through the epithelial barrier: pathogenic trickery.[J].2003,4(1).
[29]Lodi F,Pin C,Man AL,etc.Macrophage migration inhibitory factor plays a role in the regulation of microfold (M) cell-mediated transport in the gut.[J].2008,181(8).
[30]Braat H,Rottiers P,Hommes DW,etc.A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.[J].2006,4(6).
[31]Colina L,Lindh D,Citarella R,etc.Tumor inhibitory activity of anti-ras ribozymes delivered by retroviral gene transfer.[J].1996,3(4).
[32]Jean-Pierre Kraehenbuhl,Paola Ricciardi-Castagnoli,Matteo Urbano,etc.Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria[J].2001,2(4).
[33]Campbell-Thompson M,Byrne BJ,Herlihy JD,etc.Gene delivery to intestinal epithelial cells in vitro and in vivo with recombinant adeno-associated virus types 1, 2 and 5.[J].2008,53(5).
[34]Asokan A,Wu Z,Samulski RJ,etc.Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes[J].2006,80(22).
[35]Wu Y,Csencsits KL,Haddad A,etc.M cell-targeted DNA vaccination.[J].2001,98(16).